Triochem Products concluded its 54th Annual General Meeting on August 22, 2026. Shareholders unanimously approved all resolutions, including the adoption of financial statements and the re-appointment of a key director.

The meeting saw participation from 12 shareholders representing 210,840 equity shares, accounting for 86.06% of the total outstanding shares as on the book closure date of August 14, 2026. All voting was conducted via remote e-voting, with no physical ballots cast at the venue.

Financial Results Adoption

Shareholders adopted the audited financial statements for FY26. The company reported zero revenue from operations during the fiscal year ended March 31, 2026. This stands in contrast to an operational loss before exceptional items and tax of ₹64.85 lakh, a significant widening from the previous year's loss of ₹24.62 lakh. Despite the operational deficit, the Board did not recommend a dividend due to the loss position.

The voting breakdown for the adoption of financials was:

What the Numbers Show

The financial outcome for FY26 was driven almost entirely by non-operational activities. While core operations generated no revenue and incurred a ₹64.85 lakh loss, the company recognized a ₹1,116.65 lakh exceptional gain. This gain resulted from the sale of immovable properties, plant, machinery, and investment properties in Maharashtra. The assets had a written down value of ₹56.92 lakh but were sold for a fair market value totaling approximately ₹1,173.20 lakh (₹672.05 lakh for property, plant & machinery and ₹501.15 lakh net for investment properties). This indicates that the company’s reported bottom line for the year is heavily dependent on the monetization of non-core assets rather than ongoing business performance.

Governance Resolutions

Shareholders approved two additional resolutions through remote e-voting:

• Director Re-appointment: Members approved the re-appointment of Mr. Shyam Sundar Sharma as a Non-Executive, Non-Independent Director. A special resolution was passed to allow his continuation despite exceeding the age limit of 75 years, citing his 48 years of experience in industrial development and finance.
• Continuation Beyond Age Limit: A separate special resolution specifically addressed Mr. Sharma’s age (79 years), permitting his continued directorship.

Mr. Sharma, who attended all five board meetings in FY26, holds no shareholding in the company. The Statutory Auditors, M/s. Kanu Doshi Associates LLP, provided an unqualified opinion on the financial statements. The Scrutinizer for the AGM was M/s. Ragini Chokshi & Co.

Strategic Outlook

Management indicated that proceeds from the asset sales would fund new business ventures and strategic initiatives. The company stated it is focusing on trading activities expected to stabilize towards the end of FY27.

Triochem Products Limited reported a net profit of ₹9.48 lakh for the quarter ended June 30, 2026, marking a turnaround from the net loss of ₹3.06 lakh recorded in the corresponding period of FY25. The company’s total income for the quarter was ₹16.56 lakh, derived entirely from other income, as revenue from operations remained at zero.

Financial Performance

The unaudited standalone financial results, approved by the Board of Directors on August 14, 2026, reveal a significant divergence between operational activity and bottom-line performance. While the company generated no revenue from its core chemical and pharmaceuticals segment, it managed to reduce expenses to ₹4.17 lakh, down from ₹37.34 lakh in Q1FY25. This reduction was primarily driven by lower employee benefit expenses (₹0.75 lakh vs ₹13.52 lakh) and other expenditure (₹3.42 lakh vs ₹22.18 lakh).

The profit before tax stood at ₹12.39 lakh, with a total tax expense of ₹2.91 lakh comprising current tax of ₹2.63 lakh and deferred tax of ₹0.28 lakh. Earnings per share (EPS) were ₹3.87, compared to a loss of ₹1.25 per share in the previous year’s quarter.

Business Outlook and Asset Monetization

During the board meeting, directors discussed the ongoing impact of the post-COVID-19 pandemic on the business model. The company noted that sectors requiring personal presentation and relationship building have faced a "tremendous hit" with no immediate possibility of revival. Regular customer business is shrinking, with no significant improvement expected in the near term.

To address liquidity and strategic needs, Triochem previously approved the sale of certain immovable properties, plant, machinery, and investment properties in Maharashtra. Shareholder approval via postal ballot was obtained in December 2025. The assets, with a written-down value of ₹56.92 lakh, were sold for a fair market value of approximately ₹1,173.20 lakh (₹672.05 lakh for property, plant & machinery and ₹501.15 lakh for investment properties). This resulted in an exceptional gain of ₹1,116.65 lakh, which was recognized in the previous financial year’s results. The proceeds were received in cash and are proposed to be utilized for funding new business ventures and strategic initiatives.

What the Numbers Show

The current quarter’s profitability is entirely non-operational. With zero revenue from operations, the ₹9.48 lakh net profit is driven by other income exceeding minimal operational costs. This highlights the company’s transition phase, where core business activities have effectively paused while management focuses on asset monetization and potential new ventures. The sharp decline in expenses suggests a lean operational structure maintained during this period of low activity.

Regulatory Compliance

The financial results were reviewed by the Audit Committee and approved by the Board in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Kanu Doshi Associates LLP, the statutory auditors, issued an unqualified conclusion on the unaudited quarterly financial results. The company confirmed compliance with applicable securities laws and noted that there were no deviations or variations in public issues during the quarter.